500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI
500mg Fulvestrant versus Everolimus plus Exemestane in MBC patients refractory to previous AI
Breast Cancer
PFS, Progression free survival, 6 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 6 weeks
Fulvestrant versus Everolimus plus Exemestane for patients with Metastatic Breast Cancer resistant to Aromatase Inhibitors: the clinical experience from real -world